Literature DB >> 28408152

Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Kiera Rycaj1, Hangwen Li2, Jianjun Zhou3, Xin Chen4, Dean G Tang5.   

Abstract

Metastasis causes more than 90% of cancer-related deaths and most prostate cancer (PCa) patients also die from metastasis. The 'metastatic cascade' is a complex biological process that encompasses tumor cell dissociation (from the primary tumor), local invasion, intravasation, transport in circulation, extravasation, colonization, and overt growth in end organs. It has become clear that successful metastasis not only involves many tumor cell-intrinsic properties but also depends on productive interactions between cancer cells and the tumor microenvironment. In this Review, we begin with a general summary on cancer metastasis and a specific discussion on PCa metastasis. We then discuss recent advances in our knowledge of the cellular determinants of PCa metastasis and the importance of tumor microenvironment, especially an immunosuppressive tumor microenvironment, in shaping metastatic propensities. We conclude with a presentation of current and future therapeutic options for patients with PCa metastasis, emphasizing the development of novel, mechanism-based combinatorial strategies for treating metastatic and castration-resistant PCa.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Metastasis; Microenvironment; Prostate cancer

Mesh:

Year:  2017        PMID: 28408152      PMCID: PMC5491097          DOI: 10.1016/j.semcancer.2017.03.009

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  135 in total

Review 1.  Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.

Authors:  Richard M Bambury; Dana E Rathkopf
Journal:  Urol Oncol       Date:  2015-07-07       Impact factor: 3.498

2.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Authors:  Anna Johansson; Stina Rudolfsson; Peter Hammarsten; Sofia Halin; Kristian Pietras; Jonathan Jones; Pär Stattin; Lars Egevad; Torvald Granfors; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

3.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

4.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

5.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Authors:  Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen
Journal:  Lancet Oncol       Date:  2014-06-25       Impact factor: 41.316

6.  Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.

Authors:  Younghun Jung; Jin Koo Kim; Yusuke Shiozawa; Jingcheng Wang; Anjali Mishra; Jeena Joseph; Janice E Berry; Samantha McGee; Eunsohl Lee; Hongli Sun; Jianhua Wang; Taocong Jin; Honglai Zhang; Jinlu Dai; Paul H Krebsbach; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

7.  Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.

Authors:  Manish Kohli; Liguo Wang; Fang Xie; Hugues Sicotte; Ping Yin; Scott M Dehm; Steven N Hart; Peter T Vedell; Poulami Barman; Rui Qin; Douglas W Mahoney; Rachel E Carlson; Jeanette E Eckel-Passow; Thomas D Atwell; Patrick W Eiken; Brendan P McMenomy; Eric D Wieben; Gautam Jha; Rafael E Jimenez; Richard Weinshilboum; Liewei Wang
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

8.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.

Authors:  David T Miyamoto; Yu Zheng; Ben S Wittner; Richard J Lee; Huili Zhu; Katherine T Broderick; Rushil Desai; Douglas B Fox; Brian W Brannigan; Julie Trautwein; Kshitij S Arora; Niyati Desai; Douglas M Dahl; Lecia V Sequist; Matthew R Smith; Ravi Kapur; Chin-Lee Wu; Toshi Shioda; Sridhar Ramaswamy; David T Ting; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

9.  Metastatic phenotype in CWR22 prostate cancer xenograft following castration.

Authors:  Steven J Seedhouse; Hayley C Affronti; Ellen Karasik; Bryan M Gillard; Gissou Azabdaftari; Dominic J Smiraglia; Barbara A Foster
Journal:  Prostate       Date:  2015-12-08       Impact factor: 4.104

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  15 in total

Review 1.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 2.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

3.  Role of class I histone deacetylases in the regulation of maspin expression in prostate cancer.

Authors:  Eswar Shankar; Mitali Pandey; Shiv Verma; Ata Abbas; Mario Candamo; Rajnee Kanwal; Sanjeev Shukla; Gregory T MacLennan; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2020-05-11       Impact factor: 4.784

4.  MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.

Authors:  H Q Mu; Y H He; S B Wang; S Yang; Y J Wang; C J Nan; Y F Bao; Q P Xie; Y H Chen
Journal:  Clin Transl Oncol       Date:  2019-10-30       Impact factor: 3.405

Review 5.  Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.

Authors:  Sukanya Basu; Yang Dong; Rahul Kumar; Collene Jeter; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

Review 6.  Molecular determinants of prostate cancer metastasis.

Authors:  Kiera Rycaj; Dean G Tang
Journal:  Oncotarget       Date:  2017-09-19

7.  Exosome-mediated delivery of MALAT1 induces cell proliferation in breast cancer.

Authors:  Ping Zhang; Hongxing Zhou; Kefeng Lu; Yunou Lu; Yan Wang; Tongbao Feng
Journal:  Onco Targets Ther       Date:  2018-01-09       Impact factor: 4.147

8.  WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.

Authors:  Yaoyi Xiong; Lushun Yuan; Song Chen; Huimin Xu; Tianchen Peng; Lingao Ju; Gang Wang; Yu Xiao; Xinghuan Wang
Journal:  Cell Death Dis       Date:  2020-07-16       Impact factor: 8.469

Review 9.  Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.

Authors:  Joshua Altschuler; Jennifer A Stockert; Natasha Kyprianou
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

10.  Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.

Authors:  Desiree M Straign; Claire L Ihle; Meredith D Provera; Philip Owens
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.